Annual International Congress on Hematologic Malignancies | Conferences

Careful Data Review Recommended for Upfront Treatment Selection in iNHL

February 29, 2020

To enhance outcomes for patients with indolent non-Hodgkin lymphoma, an in-depth review of the available data is required. As a start, Sonali M. Smith, MD, University of Chicago Medicine, reviewed the clinical trial findings that are currently informing treatment selection in the frontline iNHL paradigm, at 24th Annual International Congress on Hematologic Malignancies.

R-CHOP Still Chosen Over Targeted Therapies in Frontline DLBCL

February 29, 2020

In an interview with Targeted Oncology, Jason Westin, MD, MS, FACP, discussed the pros and cons of administering R-CHOP in the frontline setting of diffuse large B-cell lymphoma. He also discussed other options for patients who have limited responses to the standard-of-care.

Strategic Management of CAR T-cell AEs in Hematologic Malignancies

February 29, 2020

For patients receiving chimeric antigen receptor T-cell therapy, cytokine release syndrome and neurotoxicity are the most common toxicities. A multidisciplinary approach to care is vital for these patients, explained Kimberly Noonan, DNP, ANP-BC, AOCN, in a presentation during the 24th Annual International Congress on Hematologic Malignancies.

New Data May Significantly Improve Options for Myelofibrosis Therapy Following Ruxolitinib Failure

February 28, 2020

At the 24th Annual International Congress on Hematologic Malignancies, host by Physicians’ Education Resourceâ, LLC, Ruben Mesa, MD, who is director of the UT San Antonio MD Anderson Cancer Center, presented available and emerging therapy options for patients who require additional MF therapy following ruxolitinib.

Novel Agents Continue to Advance in the Treatment Landscape of DLBCL

February 28, 2020

Because diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma in the US, clinical investigators are eager to make progress with novel agents, despite recent advances, said Craig Moskowitz, MD, in a presentation during the 2020 International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma.

Existing CAR T Cells Show Promise Even as Newer Agents Emerge in Multiple Myeloma

February 28, 2020

In an interview with Targeted Oncology at the 2020 International Congress on Hematologic Malignancies, Noopur Raje, MD, discussed emerging CAR T-cell therapies in multiple myeloma. She also explained how CAR NK cells differ from other CAR agents.